1,558
Views
5
CrossRef citations to date
0
Altmetric
Articles

Preoperative CA125 as a risk factor for symptom recurrence of adenomyosis after ultrasound-guided high-intensity focused ultrasound ablation surgery

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 1164-1169 | Received 10 May 2022, Accepted 25 Jul 2022, Published online: 08 Sep 2022

References

  • Osada H. Uterine adenomyosis and adenomyoma: the surgical approach. Fertil Steril. 2018;109(3):406–417.
  • Jeng CJ, Ou KY, Long CY, et al. 500 Cases of high-intensity focused ultrasound (HIFU) ablated uterine fibroids and adenomyosis. Taiwan J Obstet Gynecol. 2020;59(6):865–871.
  • Marques ALS, Andres MP, Kho RM, et al. Is high-intensity focused ultrasound effective for the treatment of adenomyosis? A systematic review and meta-analysis. J Minim Invasive Gynecol. 2020;27(2):332–343.
  • Guo Y, Duan H, Cheng J, et al. Gonadotrophin-releasing hormone agonist combined with high-intensity focused ultrasound ablation for adenomyosis: a clinical study. Bjog. 2017;124(Suppl 3):7–11.
  • Liu X, Wang W, Wang Y, et al. Clinical predictors of long-term success in ultrasound-guided high-intensity focused ultrasound ablation treatment for adenomyosis: a retrospective study. Medicine (Baltimore). 2016;95(3):e2443.
  • Zhang X, Zou M, Zhang C, et al. Effects of oxytocin on high intensity focused ultrasound (HIFU) ablation of adenomysis: a prospective study. Eur J Radiol. 2014;83(9):1607–1611.
  • Liu XF, Huang LH, Zhang C, et al. A comparison of the cost-utility of ultrasound-guided high-intensity focused ultrasound and hysterectomy for adenomyosis: a retrospective study. BJOG. 2017;124(Suppl 3):40–45.
  • Li X, Zhu X, He S, et al. High-intensity focused ultrasound in the management of adenomyosis: long-term results from a single center. Int J Hyperthermia. 2021;38(1):241–247.
  • Upson K, Missmer SA. Epidemiology of adenomyosis. Semin Reprod Med. 2020;38(2-03):89–107.
  • Feng T, Wei S, Wang Y, et al. Rhein ameliorates adenomyosis by inhibiting NF-kappaB and beta-Catenin signaling pathway. Biomed Pharmacother. 2017;94:231–237.
  • Kil K, Chung JE, Pak HJ, et al. Usefulness of CA125 in the differential diagnosis of uterine adenomyosis and myoma. Eur J Obstet Gynecol Reprod Biol. 2015;185:131–135.
  • Sasamoto N, Babic A, Rosner BA, et al. Predicting circulating CA125 levels among healthy premenopausal women. Cancer Epidemiol Biomarkers Prev. 2019;28(6):1076–1085.
  • Han AR, Lee TH, Kim S, et al. Risk factors and biomarkers for the recurrence of ovarian endometrioma: about the immunoreactivity of progesterone receptor isoform B and nuclear factor kappa B. Gynecol Endocrinol. 2017;33(1):70–74.
  • Sun J, Cui XW, Li YS, et al. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer. Eur Rev Med Pharmacol Sci. 2020;24(13):7276–7283.
  • Yu W, Liu G, Liu C, et al. Recurrence-associated factors of laparoscopic adenomyomectomy for severely symptomatic adenomyoma. Oncol Lett. 2018;16(3):3430–3438.
  • Reinhold C, McCarthy S, Bret PM, et al. Diffuse adenomyosis: comparison of endovaginal US and MR imaging with histopathologic correlation. Radiology. 1996;199(1):151–158.
  • Lee JS, Hong GY, Lee KH, et al. Safety and efficacy of ultrasound-guided high-intensity focused ultrasound treatment for uterine fibroids and adenomyosis. Ultrasound Med Biol. 2019;45(12):3214–3221.
  • Harter P, Sehouli J, Lorusso D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380(9):822–832.
  • Tang Y, Hu HQ, Tang YL, et al. Preoperative LMR and serum CA125 level as risk factors for advanced stage of ovarian cancer. J Cancer. 2021;12(19):5923–5928.
  • Quinn SD, Vedelago J, Kashef E, et al. Measurement of uterine fibroid volume: a comparative accuracy and validation of methods study. Eur J Obstet Gynecol Reprod Biol. 2013;171(1):161–165.
  • Yang P, Chou C, Chang C, et al. Changes in peripheral mitochondrial DNA copy number in metformin-treated women with polycystic ovary syndrome: a longitudinal study. Reprod Biol Endocrinol. 2020;18(1):69.
  • Sheth SS, Ray SS. Severe adenomyosis and CA125. J Obstet Gynaecol. 2014;34(1):79–81.
  • Zhai J, Vannuccini S, Petraglia F, et al. Adenomyosis: Mechanisms and pathogenesis. Semin Reprod Med. 2020;38(2-03):129–143.
  • Jin Z, Liu H, Xu C. Estrogen degrades scribble in endometrial epithelial cells through E3 ubiquitin ligase HECW1 in the development of diffuse adenomyosisdagger. Biol Reprod. 2020;102(2):376–387.
  • Xu X, Cai X, Liu X, et al. Possible involvement of neuropeptide and neurotransmitter receptors in adenomyosis. Reprod Biol Endocrinol. 2021;19(1):25.
  • Seeber B, Sammel MD, Fan X, et al. Panel of markers can accurately predict endometriosis in a subset of patients. Fertil Steril. 2008;89(5):1073–1081.
  • Kobayashi H, Ida W, Terao T, et al. Molecular characteristics of the CA 125 antigen produced by human endometrial epithelial cells: comparison between eutopic and heterotopic epithelial cells. Am J Obstet Gynecol. 1993;169(3):725–730.
  • Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6):415–428.